Analyst Price Target is $23.00
▲ +237.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lava Therapeutics B.V. in the last 3 months. The average price target is $23.00, with a high forecast of $24.00 and a low forecast of $22.00. The average price target represents a 237.74% upside from the last price of $6.81.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Lava Therapeutics B.V..
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.